rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
9398
|
pubmed:dateCreated |
2003-12-5
|
pubmed:commentsCorrections |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1474-547X
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:day |
29
|
pubmed:volume |
362
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1855-6; discussion 1856
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:14654329-Clinical Trials as Topic,
pubmed-meshheading:14654329-Commerce,
pubmed-meshheading:14654329-Dose-Response Relationship, Drug,
pubmed-meshheading:14654329-Drug Administration Schedule,
pubmed-meshheading:14654329-Drug Approval,
pubmed-meshheading:14654329-Drug Industry,
pubmed-meshheading:14654329-Fluorobenzenes,
pubmed-meshheading:14654329-Humans,
pubmed-meshheading:14654329-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:14654329-Hyperlipidemias,
pubmed-meshheading:14654329-Patents as Topic,
pubmed-meshheading:14654329-Pyrimidines,
pubmed-meshheading:14654329-Randomized Controlled Trials as Topic,
pubmed-meshheading:14654329-Sulfonamides
|
pubmed:year |
2003
|
pubmed:articleTitle |
The stain wars.
|
pubmed:publicationType |
Letter,
Comment
|